Full Breakdown
U.S. Supplies Experimental Antibody MBP134 for Congo Ebola Trials
6/24/2026, 2:56:08 AM
Core Event: U.S. Provides MBP134 Doses for Clinical Testing
The U.S. Department of Health and Human Services announced that stockpiled doses of the experimental monoclonal antibody MBP134, developed by San Diego-based Mapp Biopharmaceutical, will be shipped to the Democratic Republic of Congo for compassionate use and enrollment in a WHO-sponsored clinical trial. This is the first direct U.S. support of a trial in the outbreak zone, shifting from a prior policy that limited the drug to Americans at high risk.
Background & Context: Bundibugyo Ebola Outbreak in the DRC
The Bundibugyo strain of Ebola re-emerged in the DRC in early 2026, becoming the third-largest Ebola outbreak on record. The WHO declared a public health emergency for the outbreak a month ago. No vaccine or therapeutic is approved for this strain. The DRC has reported over 1,000 infections and more than 250 deaths; a handful of cases and deaths have also been recorded in neighboring Uganda.
Official Statements & Responses
- HHS said trial data could inform future regulatory review and potential U.S. approval.
- WHO said experimental treatments must be tested before wide use, logistical challenges must be addressed, and patients must have access after trials.
- WHO Director-General Tedros Ghebreyesus said vaccine trials are a little further away; CEPI chief Richard Hatchett said the coalition has the resources and plans for trial implementation.
Criticism & Operational Challenges
Officials note that conflict, disrupted supply chains, limited surveillance, community mistrust and attacks on health workers hinder trial enrollment and raise doubts about post-trial drug access.
Conflicting Reports & Gaps
The U.S. has not disclosed how many MBP134 doses will be sent. Uganda’s case count is described only as a ‘handful,’ and no efficacy data for MBP134 against Bundibugyo have been published.
Verbatim Quotes
- “We have the resources, and how the trials will be stood up and implemented, and where the Phase 1s will be done,” — Richard Hatchett, CEPI chief executive
- “Addressing these issues is a priority, the WHO said, as well as ensuring patients in the affected countries will be able to access the drugs after the trials if they are shown to be safe and effective.” — WHO spokesperson
What’s Next
The MBP134 trial, together with Gilead antivirals remdesivir and obeldesivir, will begin enrollment in the coming weeks. Phase 1 vaccine trials, including Oxford/Serum Institute of India and Moderna candidates, could start in July in the United Kingdom and possibly Uganda, pending regulatory clearance.
